436 related articles for article (PubMed ID: 25276838)
1. From bench to bedside: immunotherapy for prostate cancer.
Tse BW; Jovanovic L; Nelson CC; de Souza P; Power CA; Russell PJ
Biomed Res Int; 2014; 2014():981434. PubMed ID: 25276838
[TBL] [Abstract][Full Text] [Related]
2. Beyond sipuleucel-T: immune approaches to treating prostate cancer.
Cheng ML; Fong L
Curr Treat Options Oncol; 2014 Mar; 15(1):115-26. PubMed ID: 24402184
[TBL] [Abstract][Full Text] [Related]
3. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
[TBL] [Abstract][Full Text] [Related]
4. The evolving role of immunotherapy in prostate cancer.
Gerritsen WR
Ann Oncol; 2012 Sep; 23 Suppl 8():viii22-7. PubMed ID: 22918924
[TBL] [Abstract][Full Text] [Related]
5. New developments in castrate-resistant prostate cancer.
Shore N; Mason M; de Reijke TM
BJU Int; 2012 Jun; 109 Suppl 6():22-32. PubMed ID: 22672122
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic vaccines for prostate cancer.
Cha E; Fong L
Curr Opin Mol Ther; 2010 Feb; 12(1):77-85. PubMed ID: 20140819
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in prostate cancer: review of the current evidence.
Fernández-García EM; Vera-Badillo FE; Perez-Valderrama B; Matos-Pita AS; Duran I
Clin Transl Oncol; 2015 May; 17(5):339-57. PubMed ID: 25480118
[TBL] [Abstract][Full Text] [Related]
8. Sipuleucel-T for the treatment of advanced prostate cancer.
Frohlich MW
Semin Oncol; 2012 Jun; 39(3):245-52. PubMed ID: 22595047
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer immunotherapy: the path forward.
Madan RA; Gulley JL
Curr Opin Support Palliat Care; 2017 Sep; 11(3):225-230. PubMed ID: 28644303
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
Sun BL
Prostate; 2021 Nov; 81(15):1125-1134. PubMed ID: 34435699
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in immunotherapy for the treatment of prostate cancer.
Sonpavde G; Agarwal N; Choueiri TK; Kantoff PW
Expert Opin Biol Ther; 2011 Aug; 11(8):997-1009. PubMed ID: 21675925
[TBL] [Abstract][Full Text] [Related]
12. Current status of immunological therapies for prostate cancer.
Antonarakis ES; Drake CG
Curr Opin Urol; 2010 May; 20(3):241-6. PubMed ID: 20179598
[TBL] [Abstract][Full Text] [Related]
13. Immune-based therapies for metastatic prostate cancer: an update.
Hossain MK; Nahar K; Donkor O; Apostolopoulos V
Immunotherapy; 2018 Feb; 10(4):283-298. PubMed ID: 29421982
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for the treatment of prostate cancer.
Di Lorenzo G; Buonerba C; Kantoff PW
Nat Rev Clin Oncol; 2011 May; 8(9):551-61. PubMed ID: 21606971
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?
Laccetti AL; Subudhi SK
Curr Opin Urol; 2017 Nov; 27(6):566-571. PubMed ID: 28825923
[TBL] [Abstract][Full Text] [Related]
16. Role of immunotherapy in castration-resistant prostate cancer (CRPC).
Suárez C; Morales-Barrera R; Ramos V; Núñez I; Valverde C; Planas J; Morote J; Maldonado X; Carles J
BJU Int; 2014 Mar; 113(3):367-75. PubMed ID: 23650874
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm.
Garcia JA; Dreicer R
Oncology (Williston Park); 2011 Mar; 25(3):242-9. PubMed ID: 21548467
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer vaccines: current status and future potential.
Doehn C; Böhmer T; Kausch I; Sommerauer M; Jocham D
BioDrugs; 2008; 22(2):71-84. PubMed ID: 18345705
[TBL] [Abstract][Full Text] [Related]
19. Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer.
Patel PH; Kockler DR
Ann Pharmacother; 2008 Jan; 42(1):91-8. PubMed ID: 18094343
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 1: Prostate Cancer Vaccines.
Patel A; Fong L
Oncology (Williston Park); 2018 Mar; 32(3):112-20. PubMed ID: 29548065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
